Search
itolizumab
Indications:
- treatment of moderate COVID-19 in the elderly*
- for use in combination with other antivirals
* also see IL-6 inhibitors for COVID-19
Mechanism of action:
- anti-CD6 monoclonal antibody
- reduces plasma IL-6
Clinical trials:
- itolizumab in combination with other antivirals reduces COVID-19 disease worsening & mortality [1]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
antiviral agent
References
- Diaz Y, Ramos-Suzarte M, Martin Y et al
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly
Patients with Moderate COVID-19
Gerontology. 2020
PMID: 33105142 PMCID: PMC7649683 Free PMC article
https://www.karger.com/Article/FullText/512210